Alphatec Holdings, Inc. (NASDAQ:ATEC) General Counsel Tyson Eliot Marshall Sells 18,092 Shares

Key Points

• Tyson Eliot Marshall, General Counsel of Alphatec Holdings, sold 18,092 shares for approximately $269,752, reducing his stake by 3.96% but still retains over 438,000 shares valued at around $6.54 million.
• Alphatec's stock increased by 3.2%, reaching a price of $15.34, with a trading volume significantly higher than average at nearly 5.88 million shares.
• The company's quarterly earnings report showed an EPS of $0.02, exceeding expectations, and a 27.5% revenue increase year-over-year, with analysts predicting a consensus target price of $18.50 for the stock.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) General Counsel Tyson Eliot Marshall sold 18,092 shares of the company's stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $14.91, for a total value of $269,751.72. Following the sale, the general counsel owned 438,331 shares in the company, valued at approximately $6,535,515.21. This trade represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Tyson Eliot Marshall also recently made the following trade(s):

• On Friday, August 1st, Tyson Eliot Marshall sold 12,878 shares of Alphatec stock. The stock was sold at an average price of $12.00, for a total value of $154,536.00.
• On Thursday, July 10th, Tyson Eliot Marshall sold 1,500 shares of Alphatec stock. The stock was sold at an average price of $12.00, for a total value of $18,000.00.

Alphatec Stock Performance

ATEC traded down $0.30 on Thursday, reaching $14.90. 4,026,654 shares of the stock were exchanged, compared to its average volume of 2,070,535. The company's 50-day moving average price is $11.53 and its 200 day moving average price is $11.23. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $15.46. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77. The firm has a market capitalization of $2.20 billion, a PE ratio of -13.19 and a beta of 1.05.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.08. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. The company had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. During the same quarter in the previous year, the firm posted ($0.29) EPS. The firm's revenue was up 27.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on ATEC shares. Piper Sandler restated an "overweight" rating and set a $15.00 price objective (up from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price target on shares of Alphatec in a report on Friday, May 2nd. Barclays reiterated an "overweight" rating and issued a $22.00 price target (up from $21.00) on shares of Alphatec in a report on Monday. Canaccord Genuity Group reiterated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a report on Friday, August 1st. Finally, Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 price objective for the company in a research report on Monday, June 16th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $18.50.

Hedge Funds Weigh In On Alphatec

A number of institutional investors have recently modified their holdings of ATEC. Wealth Enhancement Advisory Services LLC lifted its position in shares of Alphatec by 301.0% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 59,987 shares of the medical technology company's stock valued at $608,000 after acquiring an additional 45,027 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Alphatec by 38,433.3% in the first quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock valued at $228,000 after purchasing an additional 2,306 shares in the last quarter. SG Americas Securities LLC grew its position in shares of Alphatec by 28.3% in the first quarter. SG Americas Securities LLC now owns 56,927 shares of the medical technology company's stock valued at $577,000 after purchasing an additional 12,553 shares in the last quarter. Oppenheimer Asset Management Inc. grew its position in shares of Alphatec by 13.4% in the first quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company's stock valued at $133,000 after purchasing an additional 1,552 shares in the last quarter. Finally, Rhumbline Advisers grew its position in shares of Alphatec by 6.9% in the first quarter. Rhumbline Advisers now owns 148,749 shares of the medical technology company's stock valued at $1,508,000 after purchasing an additional 9,661 shares in the last quarter. Hedge funds and other institutional investors own 66.35% of the company's stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.